173 related articles for article (PubMed ID: 15923430)
1. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
Bazan V; Agnese V; Corsale S; Calò V; Valerio MR; Latteri MA; Vieni S; Grassi N; Cicero G; Dardanoni G; Tomasino RM; Colucci G; Gebbia N; Russo A;
Ann Oncol; 2005 May; 16 Suppl 4():iv50-55. PubMed ID: 15923430
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
Russo A; Bazan V; Agnese V; Rodolico V; Gebbia N
Ann Oncol; 2005 May; 16 Suppl 4():iv44-49. PubMed ID: 15923428
[TBL] [Abstract][Full Text] [Related]
3. Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.
Bazan V; Bruno L; Augello C; Agnese V; Calò V; Corsale S; Gargano G; Terrasi M; Schirò V; Di Fede G; Adamo V; Intrivici C; Crosta A; Rinaldi G; Latteri F; Dardanoni G; Grassi N; Valerio MR; Colucci G; Macaluso M; Russo A;
Ann Oncol; 2006 Jun; 17 Suppl 7():vii84-90. PubMed ID: 16760301
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer.
Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Verlind E; Hermans J; Poppema S; Buys CH; Plukker JT
Dis Colon Rectum; 2001 Mar; 44(3):358-63. PubMed ID: 11289281
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
6. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
[TBL] [Abstract][Full Text] [Related]
8. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
9. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians.
Malhotra P; Anwar M; Nanda N; Kochhar R; Wig JD; Vaiphei K; Mahmood S
Tumour Biol; 2013 Jun; 34(3):1901-11. PubMed ID: 23526092
[TBL] [Abstract][Full Text] [Related]
10. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
11. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location.
Gervaz P; Bouzourene H; Cerottini JP; Chaubert P; Benhattar J; Secic M; Wexner S; Givel JC; Belin B
Dis Colon Rectum; 2001 Mar; 44(3):364-72; discussion 372-3. PubMed ID: 11289282
[TBL] [Abstract][Full Text] [Related]
12. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
Garcia-Aguilar J; Chen Z; Smith DD; Li W; Madoff RD; Cataldo P; Marcet J; Pastor C
Ann Surg; 2011 Sep; 254(3):486-92; discussion 492-3. PubMed ID: 21865946
[TBL] [Abstract][Full Text] [Related]
13. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype.
Bazan V; Migliavacca M; Zanna I; Tubiolo C; Grassi N; Latteri MA; La Farina M; Albanese I; Dardanoni G; Salerno S; Tomasino RM; Labianca R; Gebbia N; Russo A
Ann Oncol; 2002 Sep; 13(9):1438-46. PubMed ID: 12196370
[TBL] [Abstract][Full Text] [Related]
14. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
Van Cutsem E; Lenz HJ; Köhne CH; Heinemann V; Tejpar S; Melezínek I; Beier F; Stroh C; Rougier P; van Krieken JH; Ciardiello F
J Clin Oncol; 2015 Mar; 33(7):692-700. PubMed ID: 25605843
[TBL] [Abstract][Full Text] [Related]
15. Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.
Ines C; Donia O; Rahma B; Ben Ammar A; Sameh A; Khalfallah T; Abdelmajid BH; Sabeh M; Saadia B
Tumour Biol; 2014 Jul; 35(7):7163-75. PubMed ID: 24763823
[TBL] [Abstract][Full Text] [Related]
16. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutations in colorectal cancer from Tunisia: relationships with site of tumor origin, microsatellite instability and KRAS mutations.
Aissi S; Buisine MP; Zerimech F; Kourda N; Moussa A; Manai M; Porchet N
Mol Biol Rep; 2014 Mar; 41(3):1807-13. PubMed ID: 24443225
[TBL] [Abstract][Full Text] [Related]
18. Association of HPV with genetic and epigenetic alterations in colorectal adenocarcinoma from Indian population.
Laskar RS; Talukdar FR; Choudhury JH; Singh SA; Kundu S; Dhar B; Mondal R; Ghosh SK
Tumour Biol; 2015 Jun; 36(6):4661-70. PubMed ID: 25647260
[TBL] [Abstract][Full Text] [Related]
19. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
[TBL] [Abstract][Full Text] [Related]
20. A novel K-ras mutation in colorectal cancer. A case report and literature review.
Palmirotta R; Savonarola A; Formica V; Ludovici G; Del Monte G; Roselli M; Guadagni F
Anticancer Res; 2009 Aug; 29(8):3369-74. PubMed ID: 19661358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]